WINTON GROUP Ltd Sells 17,426 Shares of Roivant Sciences Ltd. $ROIV

WINTON GROUP Ltd decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 28.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 43,031 shares of the company’s stock after selling 17,426 shares during the period. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $1,523,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in ROIV. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC acquired a new position in Roivant Sciences in the fourth quarter valued at about $47,000. Parallel Advisors LLC increased its holdings in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares in the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Roivant Sciences by 7,614.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after acquiring an additional 2,665 shares in the last quarter. Finally, Clearstead Advisors LLC raised its position in shares of Roivant Sciences by 141.6% during the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock worth $63,000 after purchasing an additional 1,704 shares during the period. Institutional investors own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Jefferies Financial Group upped their price target on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Finally, Guggenheim increased their price objective on shares of Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.62.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the completion of the transaction, the chief executive officer directly owned 1,613,063 shares in the company, valued at $53,489,169.08. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daniel Gold sold 800,000 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.55, for a total value of $27,640,000.00. Following the transaction, the director directly owned 13,701,546 shares in the company, valued at $473,388,414.30. This trade represents a 5.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 3,055,913 shares of company stock valued at $107,261,258. Insiders own 8.80% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ:ROIV opened at $40.82 on Friday. The company’s 50-day moving average price is $35.79 and its two-hundred day moving average price is $31.62. Roivant Sciences Ltd. has a one year low of $13.81 and a one year high of $42.50. The stock has a market capitalization of $29.49 billion, a PE ratio of -77.02 and a beta of 1.12.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $2.06 million. On average, analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.